Daniel Martin Simadibrata
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daniel Martin Simadibrata has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
Elvira Lesmana
Faculty of Medicine Universitas Indonesia Jakarta Indonesia
7 shared publications- Yeong Yeh Lee
School of Medical Sciences Universiti Sains Malaysia Kota Bharu Kelantan Malaysia
6 shared publications Ronnie Fass
Division of Gastroenterology and Hepatology, The Esophageal and Swallowing Center MetroHealth Medical Center, Case Western Reserve University Cleveland Ohio USA
4 shared publicationsAri Fahrial Syam
Division of Gastroenterology, Department of Internal Medicine Faculty of Medicine Universitas Indonesia/Cipto Mangunkusumo Hospital Jakarta Indonesia
3 shared publicationsAlya Darin Wijaya
Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
2 shared publications- Angelos Georgiou Kolias
Division of Neurosurgery, Addenbrooke’s Hospital, Cambridge, UK
2 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (9) , e70440
Wireless Patch System, a “Holter Monitor” for the Stomach: Next Steps in Identifying Gastric Phenotypes or Just Too Much Noise?
- 15 September 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (9) , e70440
Open AccessWireless Patch System, a “Holter Monitor” for the Stomach: Next Steps in Identifying Gastric Phenotypes or Just Too Much Noise?
- 2 June 2026
- Published by Wiley in Digestive Endoscopy
- Vol. 38 (6) , e70190
Trends in Utilization of Surgical and Endoscopic Anti‐Reflux Procedures in the United States (1995–2024)
Objective: Growing concerns about the adverse effects of long‐term proton pump inhibitor use may have renewed interest in alternative treatments for gastroesophageal reflux disease (GERD), including surgical and endoscopic interventions. This study evaluated utilization trends of anti‐reflux surgical and endoscopic procedures in the United States between 1995 and 2024. Methods: A population‐based analysis was conducted using TriNetX, a database comprising 70 US healthcare organizations. GERD patients (erosive esophagitis, non‐erosive reflux disease, and Barrett's esophagus) were identified. Annual incidence rates per 100,000 GERD patients were calculated for surgical fundoplication, magnetic sphincter augmentation (LINX), endoscopic radiofrequency therapy (Stretta), and endoscopic fundoplication. Joinpoint regression analysis determined annual percentage changes (APCs) and 95% confidence intervals (95% CIs). Interrupted time‐series analysis assessed associations between major regulatory/clinical events and utilization trends. Results: Utilization of surgical fundoplication declined from 2000 to 2007 (APC −14.94%; 95% CI −25.04% to −8.69%; p = 0.002) but increased from 2007 to 2017 (APC +33.00%; 95% CI +27.15% to +59.60%; p < 0.001) and through 2024 (APC +9.04%; 95% CI −6.52% to +16.86%; p = 0.126), reaching 135.89 cases per 100,000 GERD patients. LINX saw rapid utilization starting in 2016 (APC +411.68%; 95% CI +83.91% to +921.59%; p < 0.001) but decreased after 2018 (APC −28.20%; 95% CI −52.16% to −12.40%; p = 0.002). Stretta initially increased but later plateaued (APC +40.76%; 95% CI −17.26% to +137.41%; p = 0.195). Conversely, endoscopic fundoplication demonstrated consistent growth through 2024 (APC +13.25%; 95% CI +3.91% to +23.44%; p = 0.011). Conclusions: Despite an early decline, surgical fundoplication utilization has increased over the past two decades. Endoscopic fundoplication continues to rise, while LINX and Stretta have declined over the past 7 years.
- 2 June 2026
- Published by Wiley in Digestive Endoscopy
- Vol. 38 (6) , e70190
Trends in Utilization of Surgical and Endoscopic Anti‐Reflux Procedures in the United States (1995–2024)
Objective: Growing concerns about the adverse effects of long‐term proton pump inhibitor use may have renewed interest in alternative treatments for gastroesophageal reflux disease (GERD), including surgical and endoscopic interventions. This study evaluated utilization trends of anti‐reflux surgical and endoscopic procedures in the United States between 1995 and 2024. Methods: A population‐based analysis was conducted using TriNetX, a database comprising 70 US healthcare organizations. GERD patients (erosive esophagitis, non‐erosive reflux disease, and Barrett's esophagus) were identified. Annual incidence rates per 100,000 GERD patients were calculated for surgical fundoplication, magnetic sphincter augmentation (LINX), endoscopic radiofrequency therapy (Stretta), and endoscopic fundoplication. Joinpoint regression analysis determined annual percentage changes (APCs) and 95% confidence intervals (95% CIs). Interrupted time‐series analysis assessed associations between major regulatory/clinical events and utilization trends. Results: Utilization of surgical fundoplication declined from 2000 to 2007 (APC −14.94%; 95% CI −25.04% to −8.69%; p = 0.002) but increased from 2007 to 2017 (APC +33.00%; 95% CI +27.15% to +59.60%; p < 0.001) and through 2024 (APC +9.04%; 95% CI −6.52% to +16.86%; p = 0.126), reaching 135.89 cases per 100,000 GERD patients. LINX saw rapid utilization starting in 2016 (APC +411.68%; 95% CI +83.91% to +921.59%; p < 0.001) but decreased after 2018 (APC −28.20%; 95% CI −52.16% to −12.40%; p = 0.002). Stretta initially increased but later plateaued (APC +40.76%; 95% CI −17.26% to +137.41%; p = 0.195). Conversely, endoscopic fundoplication demonstrated consistent growth through 2024 (APC +13.25%; 95% CI +3.91% to +23.44%; p = 0.011). Conclusions: Despite an early decline, surgical fundoplication utilization has increased over the past two decades. Endoscopic fundoplication continues to rise, while LINX and Stretta have declined over the past 7 years.
- 12 May 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (3)
Timeline for reinitiation of antireflux medication post-surgical or endoscopic antireflux procedures
Although various antireflux interventions are available for gastroesophageal reflux disease (GERD), the duration these interventions effectively maintain patients off antireflux medications remains inadequately characterized. This study evaluates the time to reinitiation of antireflux medications (proton pump inhibitors [PPIs] or histamine-2 receptor antagonists [H2RAs]) following surgical or endoscopic procedures for GERD. This population-based analysis utilized the U.S. Collaborative Network database within TriNetX. Adult GERD patients (≥18 years) who underwent surgical fundoplication, magnetic sphincter augmentation (LINX™), Stretta procedure, or endoscopic fundoplication were identified. The index date was defined as the date of first recorded antireflux procedure after GERD diagnosis. The primary outcome was time to reinitiation of antireflux medication (PPIs or H2RAs), analyzed using Kaplan–Meier survival curves. Secondary outcomes included time to reinitiation of PPI alone and cumulative risks of medication resumption at 1-, 5-, 10-, and 15-year post-antireflux intervention. A total of 44,343 GERD patients underwent surgical fundoplication, 868 LINX™, 294 Stretta procedure, and 510 endoscopic fundoplication. Median time to medication reinitiation was 18.2 months (95% confidence interval [95%CI] 17.7–18.8) following surgical fundoplication, with a 5-year risk of 71.6%. LINX™ demonstrated a longer median time to reinitiation (39.0, 95%CI 31.4–47.6 months) and a lower 5-year risk (59.8%). Stretta procedure and endoscopic fundoplication showed shorter median times (6.2 and 8.8 months, respectively), with almost 80% resuming medications at 5 years. Male sex was an independent predictor of PPI reinitiation following LINX™ (HR.1.623; 95%CI 1.045–2.523). Most patients who underwent surgical or endoscopic antireflux procedures resumed antireflux medications within 5 years after the intervention.
- 12 May 2026
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 39 (3)
Timeline for reinitiation of antireflux medication post-surgical or endoscopic antireflux procedures
Although various antireflux interventions are available for gastroesophageal reflux disease (GERD), the duration these interventions effectively maintain patients off antireflux medications remains inadequately characterized. This study evaluates the time to reinitiation of antireflux medications (proton pump inhibitors [PPIs] or histamine-2 receptor antagonists [H2RAs]) following surgical or endoscopic procedures for GERD. This population-based analysis utilized the U.S. Collaborative Network database within TriNetX. Adult GERD patients (≥18 years) who underwent surgical fundoplication, magnetic sphincter augmentation (LINX™), Stretta procedure, or endoscopic fundoplication were identified. The index date was defined as the date of first recorded antireflux procedure after GERD diagnosis. The primary outcome was time to reinitiation of antireflux medication (PPIs or H2RAs), analyzed using Kaplan–Meier survival curves. Secondary outcomes included time to reinitiation of PPI alone and cumulative risks of medication resumption at 1-, 5-, 10-, and 15-year post-antireflux intervention. A total of 44,343 GERD patients underwent surgical fundoplication, 868 LINX™, 294 Stretta procedure, and 510 endoscopic fundoplication. Median time to medication reinitiation was 18.2 months (95% confidence interval [95%CI] 17.7–18.8) following surgical fundoplication, with a 5-year risk of 71.6%. LINX™ demonstrated a longer median time to reinitiation (39.0, 95%CI 31.4–47.6 months) and a lower 5-year risk (59.8%). Stretta procedure and endoscopic fundoplication showed shorter median times (6.2 and 8.8 months, respectively), with almost 80% resuming medications at 5 years. Male sex was an independent predictor of PPI reinitiation following LINX™ (HR.1.623; 95%CI 1.045–2.523). Most patients who underwent surgical or endoscopic antireflux procedures resumed antireflux medications within 5 years after the intervention.
- 9 April 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Association of Body Mass Index With Disorders of Gut-Brain Interaction: A Large Global Population-Based Analysis
INTRODUCTION: Individuals with underweight or obesity may have altered gut-brain signaling. This study investigated the association between body mass index (BMI) and the prevalence and burden of disorders of gut-brain interaction (DGBI). METHODS: This cross-sectional analysis used the internet-based data from the Rome Foundation Global Epidemiology Study, conducted in 2017–2018 across 26 countries. Adults aged 18 years or older with BMI data were included. DGBI were diagnosed according to the Rome IV criteria. Associations between BMI and DGBI were analyzed across BMI categories and for each 5 kg/m 2 increment above 25 kg/m 2 using mixed logistic regression models adjusted for age, sex, diabetes, psychological distress, and healthcare utilization. Additional analyses evaluated anatomical DGBI groups, overlapping disorders, and psychometric scales. RESULTS: Among 48,366 participants, the prevalence of DGBI followed a U-shaped pattern across BMI categories. After adjustment, underweight groups had similar odds of any DGBI compared with those with normal BMI, whereas the odds progressively increased for overweight and obesity groups (class I: 1.20; 95% confidence interval [CI] 1.13–1.29; class II: 1.23; 95% CI 1.11–1.36; class III: 1.52; 95% CI 1.32–1.74). Every 5 kg/m 2 BMI increase above 25 kg/m 2 raised DGBI odds by 8% (95% CI 4%–11%). Associations were strongest for esophageal and gastroduodenal disorders. Higher BMI was associated with worse physical and mental health and greater anxiety and depression, irrespective of the presence of DGBI. DISCUSSION: Higher, but not lower, BMI is independently associated with increased prevalence and symptom burden of DGBI. Obesity confers the highest odds for overlapping disorders and psychological disturbances, underscoring the importance of integrated metabolic and behavioral management strategies.
- 9 April 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Association of Body Mass Index With Disorders of Gut-Brain Interaction: A Large Global Population-Based Analysis
INTRODUCTION: Individuals with underweight or obesity may have altered gut-brain signaling. This study investigated the association between body mass index (BMI) and the prevalence and burden of disorders of gut-brain interaction (DGBI). METHODS: This cross-sectional analysis used the internet-based data from the Rome Foundation Global Epidemiology Study, conducted in 2017–2018 across 26 countries. Adults aged 18 years or older with BMI data were included. DGBI were diagnosed according to the Rome IV criteria. Associations between BMI and DGBI were analyzed across BMI categories and for each 5 kg/m 2 increment above 25 kg/m 2 using mixed logistic regression models adjusted for age, sex, diabetes, psychological distress, and healthcare utilization. Additional analyses evaluated anatomical DGBI groups, overlapping disorders, and psychometric scales. RESULTS: Among 48,366 participants, the prevalence of DGBI followed a U-shaped pattern across BMI categories. After adjustment, underweight groups had similar odds of any DGBI compared with those with normal BMI, whereas the odds progressively increased for overweight and obesity groups (class I: 1.20; 95% confidence interval [CI] 1.13–1.29; class II: 1.23; 95% CI 1.11–1.36; class III: 1.52; 95% CI 1.32–1.74). Every 5 kg/m 2 BMI increase above 25 kg/m 2 raised DGBI odds by 8% (95% CI 4%–11%). Associations were strongest for esophageal and gastroduodenal disorders. Higher BMI was associated with worse physical and mental health and greater anxiety and depression, irrespective of the presence of DGBI. DISCUSSION: Higher, but not lower, BMI is independently associated with increased prevalence and symptom burden of DGBI. Obesity confers the highest odds for overlapping disorders and psychological disturbances, underscoring the importance of integrated metabolic and behavioral management strategies.
- 4 December 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (1) , 168-179
Rome III Versus Rome IV Criteria for Diagnosing Irritable Bowel Syndrome in a Southeast Asian Population: Insights From the Rome Foundation Global Epidemiology Study Household Survey
Introduction: Previous Asian studies have reported a substantial decline in irritable bowel syndrome (IBS) prevalence following the adoption of the Rome IV diagnostic criteria. However, comparative data on IBS prevalence using Rome III and Rome IV criteria remain sparse, especially in Southeast Asia. Methods: We analyzed household survey data from the Rome Foundation Global Epidemiology Study conducted in Malaysia and Indonesia, the only Southeast Asian countries included in the study, utilizing household‐based sampling. We compared diagnostic sensitivity between Rome III and Rome IV criteria for IBS and examined demographic characteristics, symptom severity, psychological distress, quality of life (QoL), healthcare utilization, and dietary habits among identified IBS participants. Result: Of 3411 participants (Malaysia: 2072; Indonesia: 1339), 177 (5.2%) fulfilled IBS criteria according to either Rome III or IV criteria. Among these, 115 (65%) met only the Rome III criteria, 50 (28%) met both the Rome III and IV criteria, and 12 (7%) exclusively met the Rome IV criteria. Compared with those diagnosed by Rome III, individuals identified by Rome IV criteria were younger and predominantly female. Only 31% of the Rome III IBS cases remained classified as IBS under the Rome IV criteria, while others were reclassified as unspecified bowel disorder (24%) or functional constipation (17%). While healthcare utilization rates were similar across groups, Rome IV IBS participants exhibited significantly higher symptom severity, lower anxiety levels, and poorer mental health‐related QoL. Dietary assessments revealed significantly lower intake of milk, meat products, fish, eggs, vegetables and legumes, fruit, bread, and pasta among Rome IV IBS participants. Conclusion: The Rome IV criteria for IBS demonstrate reduced diagnostic sensitivity compared with the Rome III criteria in the Southeast Asian populations. Individuals meeting the Rome IV criteria displayed distinct demographic and clinical characteristics, including greater symptom severity and reduced mental health‐related QoL.
- 4 December 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (1) , 168-179
Rome III Versus Rome IV Criteria for Diagnosing Irritable Bowel Syndrome in a Southeast Asian Population: Insights From the Rome Foundation Global Epidemiology Study Household Survey
Introduction: Previous Asian studies have reported a substantial decline in irritable bowel syndrome (IBS) prevalence following the adoption of the Rome IV diagnostic criteria. However, comparative data on IBS prevalence using Rome III and Rome IV criteria remain sparse, especially in Southeast Asia. Methods: We analyzed household survey data from the Rome Foundation Global Epidemiology Study conducted in Malaysia and Indonesia, the only Southeast Asian countries included in the study, utilizing household‐based sampling. We compared diagnostic sensitivity between Rome III and Rome IV criteria for IBS and examined demographic characteristics, symptom severity, psychological distress, quality of life (QoL), healthcare utilization, and dietary habits among identified IBS participants. Result: Of 3411 participants (Malaysia: 2072; Indonesia: 1339), 177 (5.2%) fulfilled IBS criteria according to either Rome III or IV criteria. Among these, 115 (65%) met only the Rome III criteria, 50 (28%) met both the Rome III and IV criteria, and 12 (7%) exclusively met the Rome IV criteria. Compared with those diagnosed by Rome III, individuals identified by Rome IV criteria were younger and predominantly female. Only 31% of the Rome III IBS cases remained classified as IBS under the Rome IV criteria, while others were reclassified as unspecified bowel disorder (24%) or functional constipation (17%). While healthcare utilization rates were similar across groups, Rome IV IBS participants exhibited significantly higher symptom severity, lower anxiety levels, and poorer mental health‐related QoL. Dietary assessments revealed significantly lower intake of milk, meat products, fish, eggs, vegetables and legumes, fruit, bread, and pasta among Rome IV IBS participants. Conclusion: The Rome IV criteria for IBS demonstrate reduced diagnostic sensitivity compared with the Rome III criteria in the Southeast Asian populations. Individuals meeting the Rome IV criteria displayed distinct demographic and clinical characteristics, including greater symptom severity and reduced mental health‐related QoL.
- 2 April 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (6) , 1472-1484
Epidemiology and Impact of Disorders of Gut–Brain Interaction in Multiethnic Malaysia: An In‐Depth Analysis of Local Data From the Rome Foundation Global Epidemiology Study
Introduction: Previous epidemiology studies from Malaysia on disorders of gut–brain interaction (DGBI) have utilized variable criteria. Furthermore, the impact of DGBI on quality of life (QoL), healthcare utilization, diet, work productivity, and sleep in a multiethnic Asian setting like Malaysia remains underexplored. Here, we aimed to determine the epidemiology and impact of DGBI among multiethnic Malaysians based on the Rome IV criteria.Methods: 2072 Malaysian participants from the Rome Foundation Global Epidemiology Study (RFGES) with complete data on DGBI were included in the in‐depth analysis. We assessed the prevalence of DGBI diagnoses, psychological distress, QoL, healthcare utilization, dietary patterns, impact on sleep, work productivity, and activity impairment.Results: The overall prevalence of any DGBI in Malaysia was 19.3% (95% CI 17.6%–21.0%). The top three most prevalent DGBI diagnoses were functional constipation (5.1%; 95% CI 4.2%–6.1%), functional dyspepsia (3.4%; 95% CI 2.7%–4.3%), and functional diarrhea (1.6%; 95% CI 1.1%–2.2%). Participants with DGBI reported higher levels of psychological distress (somatization, anxiety, and depression), significantly higher healthcare utilization, and dietary change (low FODMAPs but higher Mediterranean‐based diet and probiotics). Furthermore, there was greater daytime sleepiness and higher proportions of presenteeism, overall work impairment, and activity impairment in individuals with DGBI.Conclusion: The disease burden of DGBI is significant in Malaysia, with increased psychological distress, healthcare utilization, dietary change, greater daytime sleepiness, and greater overall work and activity impairment.
- 2 April 2025
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 40 (6) , 1472-1484
Epidemiology and Impact of Disorders of Gut–Brain Interaction in Multiethnic Malaysia: An In‐Depth Analysis of Local Data From the Rome Foundation Global Epidemiology Study
Introduction: Previous epidemiology studies from Malaysia on disorders of gut–brain interaction (DGBI) have utilized variable criteria. Furthermore, the impact of DGBI on quality of life (QoL), healthcare utilization, diet, work productivity, and sleep in a multiethnic Asian setting like Malaysia remains underexplored. Here, we aimed to determine the epidemiology and impact of DGBI among multiethnic Malaysians based on the Rome IV criteria.Methods: 2072 Malaysian participants from the Rome Foundation Global Epidemiology Study (RFGES) with complete data on DGBI were included in the in‐depth analysis. We assessed the prevalence of DGBI diagnoses, psychological distress, QoL, healthcare utilization, dietary patterns, impact on sleep, work productivity, and activity impairment.Results: The overall prevalence of any DGBI in Malaysia was 19.3% (95% CI 17.6%–21.0%). The top three most prevalent DGBI diagnoses were functional constipation (5.1%; 95% CI 4.2%–6.1%), functional dyspepsia (3.4%; 95% CI 2.7%–4.3%), and functional diarrhea (1.6%; 95% CI 1.1%–2.2%). Participants with DGBI reported higher levels of psychological distress (somatization, anxiety, and depression), significantly higher healthcare utilization, and dietary change (low FODMAPs but higher Mediterranean‐based diet and probiotics). Furthermore, there was greater daytime sleepiness and higher proportions of presenteeism, overall work impairment, and activity impairment in individuals with DGBI.Conclusion: The disease burden of DGBI is significant in Malaysia, with increased psychological distress, healthcare utilization, dietary change, greater daytime sleepiness, and greater overall work and activity impairment.
- Open Access
Tegoprazan‐Containing Versus Proton Pump Inhibitor‐Containing Therapy for First‐Line Eradication of Helicobacter pylori: A Meta‐Analysis of Randomized Controlled Trials
Introduction: Concerns have been raised regarding the decreasing success rates of the standard treatment of Helicobacter pylori (proton pump inhibitor (PPI) and two/three antibiotics) and the long‐term effects carried by PPI. Despite conflicting data, Tegoprazan, a potassium‐competitive acid blocker, is hypothesized to be superior to PPI for eradicating H pylori. This systematic review and meta‐analysis aim to determine the superiority of Tegoprazan‐containing therapy to PPI‐containing therapy for H pylori eradication.Methods: A systematic literature search identified studies published until December 12, 2024, from MEDLINE, EMBASE, SCOPUS, and CENTRAL. The search strategy included the following keywords: “Tegoprazan,” “Proton Pump Inhibitors,” and “Helicobacter pylori.” Only randomized controlled trials (RCTs) that compared the efficacy of Tegoprazan to any PPI were included. Risk of bias assessment was performed using the Cochrane Risk of Bias 2 (RoB2) tool for RCTs. The random‐effect model was used to calculate the pooled risk ratio (RR) and its 95% Confidence Interval (95% CI) from the intention‐to‐treat population.Results: Six RCTs with low risks of bias were included in this meta‐analysis. All studies included treatment‐naïve patients and compared first‐line H pylori treatment. The overall eradication rates of Tegoprazan‐containing (N = 1052) versus PPI‐containing therapy (N = 1058) were 83.37% and 80.06%, respectively (RR 1.045; 95% CI 1.008–1.084; I2 = 0%). Tegoprazan‐containing therapy demonstrated comparable treatment‐emergent adverse event (TEAE) rates compared to PPI‐containing therapy (46.48% vs. 46.31%; RR 1.026; 95% CI 0.952–1.106; I2 = 48%).Conclusion: This meta‐analysis demonstrated that Tegoprazan‐containing therapy is superior to PPI‐containing therapy for first‐line H pylori eradication, with comparable safety profiles.
Open AccessTegoprazan‐Containing Versus Proton Pump Inhibitor‐Containing Therapy for First‐Line Eradication of Helicobacter pylori: A Meta‐Analysis of Randomized Controlled Trials
Introduction: Concerns have been raised regarding the decreasing success rates of the standard treatment of Helicobacter pylori (proton pump inhibitor (PPI) and two/three antibiotics) and the long‐term effects carried by PPI. Despite conflicting data, Tegoprazan, a potassium‐competitive acid blocker, is hypothesized to be superior to PPI for eradicating H pylori. This systematic review and meta‐analysis aim to determine the superiority of Tegoprazan‐containing therapy to PPI‐containing therapy for H pylori eradication.Methods: A systematic literature search identified studies published until December 12, 2024, from MEDLINE, EMBASE, SCOPUS, and CENTRAL. The search strategy included the following keywords: “Tegoprazan,” “Proton Pump Inhibitors,” and “Helicobacter pylori.” Only randomized controlled trials (RCTs) that compared the efficacy of Tegoprazan to any PPI were included. Risk of bias assessment was performed using the Cochrane Risk of Bias 2 (RoB2) tool for RCTs. The random‐effect model was used to calculate the pooled risk ratio (RR) and its 95% Confidence Interval (95% CI) from the intention‐to‐treat population.Results: Six RCTs with low risks of bias were included in this meta‐analysis. All studies included treatment‐naïve patients and compared first‐line H pylori treatment. The overall eradication rates of Tegoprazan‐containing (N = 1052) versus PPI‐containing therapy (N = 1058) were 83.37% and 80.06%, respectively (RR 1.045; 95% CI 1.008–1.084; I2 = 0%). Tegoprazan‐containing therapy demonstrated comparable treatment‐emergent adverse event (TEAE) rates compared to PPI‐containing therapy (46.48% vs. 46.31%; RR 1.026; 95% CI 0.952–1.106; I2 = 48%).Conclusion: This meta‐analysis demonstrated that Tegoprazan‐containing therapy is superior to PPI‐containing therapy for first‐line H pylori eradication, with comparable safety profiles.
- Open Access
- 28 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6457
Diagnostic Accuracy Performance of Fluorescence In Situ Hybridization (FISH) for Biliary Strictures: A Systematic Review and Meta-Analysis
Background and Aims: This systematic review and meta-analysis aims to compare the performance of UroVysion® FISH based on the different definitions of a positive result used in published literature with the goal of determining the optimal FISH definition for detecting pancreaticobiliary malignancy. Methods: A systematic literature search identified studies from database inception to Sept 2024 that evaluated the diagnostic performance of FISH in determining malignancy among patients with biliary strictures. All thresholds for positive FISH, as defined by the individual study, were included in this review. Subgroup analysis was performed based on the definitions of positive FISH as follows: (1) polysomy only; (2) polysomy, tetrasomy, or trisomy; and (3) polysomy or 9p deletion. Results: Eighteen studies comprising 2516 FISH specimens were analyzed, including 1133 (45.0%) with malignancy. Using a threshold for positivity as defined in individual studies, the overall sensitivity of FISH was 57.6% (95% confidence interval [CI], 49.4–65.4%), and the overall specificity was 87.8% (95% CI, 79.2–93.2%). Subgroup analysis showed that polysomy as the threshold for positive FISH yielded a sensitivity of 49.4% (95% CI, 43.2–55.5%), with an increased specificity of 96.2% (95% CI, 92.7–98.1%), while polysomy + tetrasomy/trisomy as positive FISH resulted in an increased sensitivity of 64.3% (95% CI 55.4–72.2%) but a decreased specificity of 78.9% (95% CI 64.4–88.5%). The addition of 9p deletion to polysomy as the criteria for a positive test resulted in a non-significant increase in sensitivity (54.7% (95% CI 42.4–66.5%) while maintaining specificity (95.1% (95% CI 84.0–98.6%). Conclusions: Based on these findings, polysomy only or polysomy/9p deletion should be considered as the criterion for defining a positive FISH test to improve diagnostic sensitivity while maintaining high specificity.
- 28 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6457
Open AccessDiagnostic Accuracy Performance of Fluorescence In Situ Hybridization (FISH) for Biliary Strictures: A Systematic Review and Meta-Analysis
Background and Aims: This systematic review and meta-analysis aims to compare the performance of UroVysion® FISH based on the different definitions of a positive result used in published literature with the goal of determining the optimal FISH definition for detecting pancreaticobiliary malignancy. Methods: A systematic literature search identified studies from database inception to Sept 2024 that evaluated the diagnostic performance of FISH in determining malignancy among patients with biliary strictures. All thresholds for positive FISH, as defined by the individual study, were included in this review. Subgroup analysis was performed based on the definitions of positive FISH as follows: (1) polysomy only; (2) polysomy, tetrasomy, or trisomy; and (3) polysomy or 9p deletion. Results: Eighteen studies comprising 2516 FISH specimens were analyzed, including 1133 (45.0%) with malignancy. Using a threshold for positivity as defined in individual studies, the overall sensitivity of FISH was 57.6% (95% confidence interval [CI], 49.4–65.4%), and the overall specificity was 87.8% (95% CI, 79.2–93.2%). Subgroup analysis showed that polysomy as the threshold for positive FISH yielded a sensitivity of 49.4% (95% CI, 43.2–55.5%), with an increased specificity of 96.2% (95% CI, 92.7–98.1%), while polysomy + tetrasomy/trisomy as positive FISH resulted in an increased sensitivity of 64.3% (95% CI 55.4–72.2%) but a decreased specificity of 78.9% (95% CI 64.4–88.5%). The addition of 9p deletion to polysomy as the criteria for a positive test resulted in a non-significant increase in sensitivity (54.7% (95% CI 42.4–66.5%) while maintaining specificity (95.1% (95% CI 84.0–98.6%). Conclusions: Based on these findings, polysomy only or polysomy/9p deletion should be considered as the criterion for defining a positive FISH test to improve diagnostic sensitivity while maintaining high specificity.
- 30 August 2024
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 33 (10) , 1009-1018
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?
Proton pump inhibitor (PPI) has revolutionized the treatment of erosive esophagitis (EE) in the past few decades. However, roughly 30-40% of patients, especially with severe EE (Los Angeles Grade C/D), remain poorly responsive to this medication. Novel drugs have been formulated and/or repurposed to address this problem. This review highlights novel drugs that have been investigated for use in EE, such as mucosal protectants, prokinetics, transient lower esophageal sphincter relaxation (TLESR) reducers, novel PPIs, and the new potassium-competitive acid blocker (PCAB). Studies have demonstrated that PCAB has promising results (efficacy and safety) compared to PPI for the healing of EE, especially in severe diseases. PCAB has gained interest in recent years, with pharmacokinetics and pharmacodynamics properties surpassing PPI. Although recent data on PCABs, which comprised mainly of Vonoprazan, have shown promising results, more randomized controlled trials for other PCAB drugs are needed to elucidate and confirm the superiority of this drug class to PPI, the current first-line treatment of EE.
- 30 August 2024
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 33 (10) , 1009-1018
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?
Proton pump inhibitor (PPI) has revolutionized the treatment of erosive esophagitis (EE) in the past few decades. However, roughly 30-40% of patients, especially with severe EE (Los Angeles Grade C/D), remain poorly responsive to this medication. Novel drugs have been formulated and/or repurposed to address this problem. This review highlights novel drugs that have been investigated for use in EE, such as mucosal protectants, prokinetics, transient lower esophageal sphincter relaxation (TLESR) reducers, novel PPIs, and the new potassium-competitive acid blocker (PCAB). Studies have demonstrated that PCAB has promising results (efficacy and safety) compared to PPI for the healing of EE, especially in severe diseases. PCAB has gained interest in recent years, with pharmacokinetics and pharmacodynamics properties surpassing PPI. Although recent data on PCABs, which comprised mainly of Vonoprazan, have shown promising results, more randomized controlled trials for other PCAB drugs are needed to elucidate and confirm the superiority of this drug class to PPI, the current first-line treatment of EE.
- Open Access
- 26 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3740
Clostridioides difficile Infection in the Elderly: Trend Analysis from 2000 to 2019
Background/Objective: Clostridioides difficile infection (CDI) is a common healthcare-associated ailment, presenting major health and economic challenges, especially for the elderly. Despite its prevalence, comprehensive data about CDI’s impact on the elderly are limited. Methods: This study used the Global Burden of Disease Study 2019 data to analyze CDI trends from 2000 to 2019, considering factors like sex, region, and sociodemographic index (SDI). Results: This study revealed that CDI caused approximately 18,181 deaths and 252,709 disability-adjusted life years (DALYs) among the elderly worldwide. The Americas showed the highest CDI burden, while the Eastern Mediterranean saw the steepest rate increase from 2000 to 2019. Regions with a high SDI also displayed substantial CDI impact. Conclusions: The escalating burden of CDI in the elderly, especially in high-SDI areas and the Americas, emphasizes an urgent need for targeted public health strategies.
- 26 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3740
Open AccessClostridioides difficile Infection in the Elderly: Trend Analysis from 2000 to 2019
Background/Objective: Clostridioides difficile infection (CDI) is a common healthcare-associated ailment, presenting major health and economic challenges, especially for the elderly. Despite its prevalence, comprehensive data about CDI’s impact on the elderly are limited. Methods: This study used the Global Burden of Disease Study 2019 data to analyze CDI trends from 2000 to 2019, considering factors like sex, region, and sociodemographic index (SDI). Results: This study revealed that CDI caused approximately 18,181 deaths and 252,709 disability-adjusted life years (DALYs) among the elderly worldwide. The Americas showed the highest CDI burden, while the Eastern Mediterranean saw the steepest rate increase from 2000 to 2019. Regions with a high SDI also displayed substantial CDI impact. Conclusions: The escalating burden of CDI in the elderly, especially in high-SDI areas and the Americas, emphasizes an urgent need for targeted public health strategies.